Autolus Therapeutics is a biopharmaceutical company developing programmed T cell therapies for the treatment of cancer. Co.'s clinical-stage programs include: AUTO1, a CD19-targeting programmed T cell investigational therapy with a CD19 binder; AUTO3, a dual-targeting, bicistronic, or having two chimeric antigen receptors within one vector, programmed T cell investigational therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma independently targeting B-lymphocyte antigens CD19 and CD22; and AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1.
|
Free AUTL Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Strong Buy (3.62 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Analysts' Target Price: AUTL Stock Forecast Based on Zacks ABR data; powered by Xignite |